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Abstract
AIM
To evaluate the anti-inflammatory intestinal effect of 
the ethanolic extract (EtOHE) and hexane phase (HexP) 
obtained from the leaves of Combretum duarteanum 
(Cd).
METHODS
Inflammatory bowel disease was induced using 
trinitrobenzenesulfonic acid in acute and relapsed 
ulcerative colitis in rat models. Damage scores, and 
biochemical, histological and immunohistochemical 
parameters were evaluated. 
RESULTS
Both Cd -EtOHE and Cd -HexP caused significant 
reductions in macroscopic lesion scores and ulcerative 
lesion areas. The vegetable samples inhibited 
myeloperoxidase increase, as well as pro-inflammatory 
cytokines TNF-α and IL-1β. Anti-inflammatory cytokine 
IL-10 also increased in animals treated with the tested 
plant samples. The anti-inflammatory intestinal effect is 
related to decreased expression of cyclooxygenase-2, 
proliferating cell nuclear antigen, and an increase in 
superoxide dismutase. 
CONCLUSION
The data indicate anti-inflammatory intestinal activity. 
The effects may also involve participation of the 
antioxidant system and principal cytokines relating to 
inflammatory bowel disease. 
Key words: Combretum duarteanum; Medicinal plants; 
Combretaceae; Inflammatory bowel disease; Anti-
inflammatory intestinal activity
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Core tip: Inflammatory bowel diseases are chronic 
inflammatory disorders that include Crohn’s disease 
and ulcerative colitis (UC). Genetic, immunologic 
and environmental factors are postulated as possible 
etiologic agents. Their conventional treatment is 
centered in reducing inflammation and abnormal 
symptom relief. A variety of herbal medicines have 
been demonstrated to produce promising results in the 
treatment of those diseases. Combretum duarteanum 
is a species popularly used in folk medicine to treat 
inflammation. Thus, the present study was designed 
to evaluate the intestinal anti-inflammatory effect in 
an UC rat model, contributing to the safe use and 
collaborating with the scientific knowledge of natural 
products. 
de Morais Lima GR, Machado FDF, Périco LL, de Faria FM, 
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INTRODUCTION
The inflammatory bowel diseases (IBDs) are chronic 
disorders of the gastrointestinal (GI) tract characterized 
by alternating periods of remission and relapse[1]. These 
diseases represent a large group of inflammatory 
disorders, the most common being Crohn’s disease (CD) 
and ulcerative colitis (UC)[2,3].
CD can affect any part of the GI tract and has the 
classic symptoms of fatigue, prolonged diarrhea (with 
or without bleeding), abdominal pain, weight loss, and 
fever[4,5]. UC is a type of chronic inflammation restricted 
to the colon; however, the entire large intestine may be 
affected[6]. Affected patients show symptoms such as 
rectal bleeding, frequent bowel movements, tenesmus, 
rectal mucus discharge, and abdominal pain[5].
The etiology of IBDs is still not fully understood; 
however, it is believed that environmental, genetic 
and immunologic factors have important roles in their 
occurrence and progression[4,7].
Emerging models in the study of IBD pathogenesis 
suggest three key disease development factors: (1) 
breaking the intestinal barrier function; (2) lamina 
immune cell exposure to luminal contents; and (3) 
exacerbation of immune response. However, the 
factors responsible for initiation and perpetuation of 
the cycle leading to exacerbation of the disease are 
still unclear[8,9].
A combination of genetic and environmental factors 
may foment changes in the intestinal mucosal barrier 
function; this allows translocation of luminal antigens 
(commensal bacteria or microbial products) into the 
intestinal wall, and consequent immune cell activation 
and excessive production of cytokines, causing the 
acute phase of inflammation. If the acute inflamma­
tory process is not resolved by anti­inflammatory 
mechanisms and suppression of pro­inflammatory 
cytokines, chronic intestinal inflammation develops. 
This can lead to tissue destruction and complications of 
the disease[10].
Conventional treatments are aimed at reducing 
inflammation and consequent abnormal symptom relief. 
Patients with UC are treated with amino­salicylates, 
corticosteroids, and immunomodulatory drugs[11].
Natural products have become the most attractive 
source of new drugs for the treatment and prevention 
of diseases and their use is constantly expanding 
worldwide. A variety of herbal medicines have been 
shown to produce promising results in the treatment 
of peptic ulcer and IBD[11­14]. 
Combretum duarteanum (C. duarteanum, Cd) 
Cambess., the species selected for this study, is 
popularly known as “mufumbo, cipiúba, cipaúba”. This 
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shrubby species is exclusive to South America with 
registrations in Bolivia, Paraguay, and Brazil. It occurs 
in the northern and northeastern regions of Brazil, 
being associated with the “caatinga” biome[15,16].
In folk medicine, C. duarteanum is used to treat 
pain, inflammation and GI tract disorders, which justifies 
its selection, using ethno­pharmacological indication as 
the criterion of choice. Phytochemical studies suggest 
the presence of flavonoids and triterpenes, whose 
pharmacological effects have been attributed[16­18].
C. duarteanum has presented in vitro and in vivo 
anti­inflammatory, anti­nociceptive, and antioxidant 
capacities[15]. Quintans et al[17] demonstrated orofacial 
nociceptive activity as promoted by the hexane phase 
and Fridelin terpenes, isolated from the species 
studied.
de Morais Lima et al[16,19] demonstrated gastro­
protective and antiulcer activity in C. duarteanum in 
different models of acute ulcer induction (acidified 
ethanol, ethanol, nonsteroidal anti­inflammatory drugs 
(commonly known as NSAIDs), stress, pylorus ligature, 
acetic acid) in animals. Previous studies demonstrated 
low toxicity and no change of liver enzymes in animals 
treated with the tested plant sample for 15 d in acid 
acetic­induced gastric ulcer model[19].
Given the need for new IBD therapies, this study 
aimed to evaluate the intestinal anti­inflammatory 
activity promoted by the species C. duarteanum, 
validating its popular use and contributing to the 
search for new therapies for diseases that affect the GI 
tract.
MATERIALS AND METHODS
Reagents
The drugs and reagents were prepared immediately 
before use. The following drugs were used: trinitro­
benzenesulfonic acid (TNBS) (Sigma­Aldrich), ketamine 
5% (Vetanarcol), xilazine 2% (Dorcipec), ethanol 
(Merck®), Tween 80 (Merck®), sodium chloride (Sigma­
Aldrich). TNF­α, IL­1β and IL­10 in enzyme­linked 
immunosorbent assay (ELISA) kits were provided by 
R&D Systems Inc.
Plant material 
Plant samples used in intestinal anti­inflammatory 
activity research experiments in rats were obtained 
from the leaves of C. duarteanum Cambess., collected 
at Serra Branca City, Paraíba State, Brazil, in 2010. 
The species was identified by Dr. Maria Fatima Agra 
and a voucher specimen (No. 6767) was deposited 
in the Herbarium Prof. Lauro Pires Xavier (JPB) at the 
Universidade Federal da Paraíba.
The ethanolic extract (Cd­EtOHE) and the hexane 
phase (Cd­HexP) obtained from the leaves of C. 
duarteanum Cambess. were provided by Dr. Josean 
Fechine Tavares and his group, all of PgPNSB/UFPB.
The dried leaves (5 kg) were powdered, extracted 
with ethanol, stirred, and macerated at room tem­
perature for approximately 48 h, with the procedure 
being repeated three times. The solvent was fully 
evaporated under reduced pressure, and the extract 
(yield of 200 g) was concentrated. The Cd­EtOHE was 
subjected to liquid­liquid partition with the following 
solvents: hexane, chloroform (CHCl3), and ethyl acetate 
(EtOAc), obtaining their respective phases. This step 
was repeated to secure the required quantity for the 
study.
Pharmacological assays
Investigation of Cd-EtOHE and Cd-HexP effects 
on acute phase intestinal inflammation (TNBS)-
induced in rats: The intestinal anti­inflammatory 
activity of Cd­EtOHE and Cd­HexP was assessed in rats 
using the Morris et al[20] method. Male Wistar rats (n 
= 5­8) fasted for 24 h were divided into four groups: 
non­colitic, colitic, Cd­EtOHE and Cd­HexP. The 
animals were anesthetized for rectal administration 
of TNBS (2,4,6­trinitro­benzene sulfonic acid) ­ 10 
mg solubilized in 0.25 mL of 50% v/v ethanol. The 
induction of inflammation was performed with the 
aid of a probe (2­mm diameter), which was inserted 
about 8 cm into the rectum of the animal. After TNBS 
administration, animals were maintained upside 
down for 15 min to enable total absorption of the 
administered inducing agent. The non­colitic group 
underwent the same procedures but they did not 
receive TNBS.
Each group of rats was pretreated with vehicle (12% 
Tween 80), Cd­EtOHE (31.25, 62.5, 125, 250 mg/kg) 
or Cd­HexP (31.25, 62.5, 125, 250 mg/kg), at 48, 24 
and 1 h prior to administration of TNBS/50% ethanol, 
and at 24 h after colitis induction. At 48 h after 
inducing inflammation, the animals were euthanized 
and colonic segments were removed, opened, washed, 
and photographed for quantification of ulcerative 
lesion area (ULA) and macroscopic score evaluation 
of the intestinal inflammatory process. Analysis of the 
extent of intestinal injury was performed according to 
the scale described previously by Bell et al[21]. General 
parameters such as diarrhea and the colon weight/
length ratio were also evaluated. The most effective 
doses obtained in this model were used in the chronic 
model with relapse of UC in rats.
Investigation of Cd-EtOHE and Cd-HexP effects 
in the chronic phase with intestinal inflammation 
relapse induced by TNBS in rats: Male Wistar rats (n 
= 7­9) were divided into non­colitic, colitic, Cd­EtOHE 
and Cd­Hexp groups. After 24 h of fasting, induction of 
intestinal inflammation was performed with TNBS (10 
mg/0.25 mL ethanol 50% v/v, rectally)[20]. At 24 h after 
initial induction, the animal groups were treated orally 
with 12% Tween 80 solution (non­colitic and colitic), Cd­
EtOHE (125 mg/kg) or Cd­HexP (62.5 mg/kg). On day 
14 after the first induction, the second administration 
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using ELISA assay kits (DuoSet®; R & D Systems Inc.). 
The concentrations of the cytokines in relation to the 
amount of total protein was quantified by bicinchoninic 
acid method[24]. 
Immunohistochemical analysis cyclooxygenase-2, 
proliferating cell nuclear antigen, and superoxide 
dismutase expression
Histological samples were incubated with anti­cyclo­
oxygenase­2 (COX­2) secondary antibody (marker for 
assessing anti­inflammatory effect), anti­proliferating 
cell nuclear antigen (PCNA) (cell division marker to 
assess potential for regeneration), and anti­superoxide 
dismutase (SOD) (marker to evaluate the antioxidant 
effect). The positively stained cells were counted for 
the various immunohistochemical reactions in a fixed 
number of fields by means of an image analyzer (Q­Win 
Standard Version 3.1.0; Leica) coupled to the Leica DM 
microscope. They were photographed and analyzed by 
AVSoft program Bioview Spectra and Seeker 4.0.
Animal care and use statement
The experimental protocols were approved by the 
Committee for Ethics in Animal Experimentation (CEPA/
LTF/UFPB) under number 1112/10. Male Wistar albino 
rats (180­250 g) from the “Prof. Thomas George 
Vivarium” of LTF/UFPB were fed a certified Presence® 
diet, with free access to water under fixed conditions of 
illumination (12/12 h light/dark cycle), humidity (60% 
± 1.0%), and temperature (21.5 ± 1.0 ℃). Fasting 
was used prior to all assays since standard drugs were 
administered orally (by gavage) or by intra­rectal 
route, using a 12% solution of Tween 80 (10 mL/kg) 
as the vehicle. The animals were kept in cages with 
raised, wide­mesh floors to prevent coprophagy.
Statistical analysis
Results with parameter values (inflammatory bowel 
lesion area and weight/length ratio) were subjected 
to analysis of variance (ANOVA) followed by Dunnett’s 
or Tukey test, and expressed as mean ± SD of the 
average. In quantitation assays of antioxidant enzymes, 
cytokines and MPO values obtained were presented as 
mean ± standard error of mean (SEM).
For nonparametric values (score of intestinal 
inflammation), the Kruskal­Wallis test (ANOVA, Dunn's 
post­test) was used. The results were expressed as 
median (minimum­maximum). Data were analyzed 
using the software GraphPad Prism 6.0, and the 
significance level was set at p < 0.05.
RESULTS
Investigation of Cd-EtOHE and Cd-HexP effect on 
induced acute phase intestinal inflammation (TNBS) in 
rats
A significant reduction in the intestinal ULA for rats 
(relapse) was performed with TNBS (10 mg/0.25 mL 
ethanol 50% v/v, rectally) to mimic recurrent relapses 
in IBDs in humans.
General parameters such as diarrhea, water and 
food intake, and body weight were recorded daily 
throughout the treatment period. At day 21 all animals 
were euthanized, the colon removed, opened, and 
washed for macroscopic lesion analysis and evaluation 
of the intestinal inflammatory process[21]. Collection of 
material for biochemical and histological analysis was 
also performed. The samples were stored at ­80 ℃ for 
evaluation of myeloperoxidase (MPO) and cytokines 
involved in intestinal inflammation.
Histological analysis
Colonic segments intended for light microscopy were 
collected. For this, the tissues were fixed in Alfac 
solution for 24 h at room temperature. Afterwards, 
the pieces were kept in 80% alcohol until the block 
assembly time. The pieces were dehydrated and 
embedded in paraplast forming blocks, and then cut to 
10­mm thickness for mounting on slides. These were 
stained with hematoxylin and eosin for morphological 
analysis[22].
Quantification of MPO activity
Colon segments, stored at ­80 ℃ were used with 
dosages of MPO and pro­inflammatory and anti­
inflammatory cytokines. The samples were homo­
genized in hexadecyltrimethylammonium bromide 
buffer (HTAB) (0.5% in 50 mmol/L sodium phosphate 
buffer, pH 6.0) that acts as a detergent, lysing granules 
of neutrophils containing MPO, which is released. 
The sample was centrifuged for 10 min at 4 ℃. The 
homogenate was subjected to a three­fold freezing 
and thawing process to facilitate the rupturing of cell 
structures and the consequent release of the enzyme. 
On ELISA plates were placed 50 μL of supernatant 
from each sample and 150 μL of reaction buffer[23].
The results were expressed as MPO units per gram 
of tissue, where 1 U of MPO activity is defined as that 
degrading 1 μmol of hydrogen peroxide per min at 
25 ℃.
Assessment of the involvement of pro-inflammatory 
(TNF-α  and IL-1β ) and anti-inflammatory cytokines 
(IL-10)
TNF­α, IL­1β and IL­10 levels were determined from 
colonic specimens, frozen in ­80 ℃, and collected in the 
UC relapse model. For this, we used PBS buffer pH 7.4 
(1:5) to homogenize the samples. The homogenate 
tubes were centrifuged at 12000 rpm for 10 min. 
The supernatants were frozen at ­80 ℃ until assay. 
Subsequently, the samples were shaken in water bath 
at 37 ℃ for 20 min and then centrifuged at 10000 rpm 
for 5 min at 4 ℃. The supernatant was collected and 
the cytokines TNF­α, IL­1β and IL­10 were quantitated 
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treated with Cd­EtOHE at doses of 62.5 and 125 
mg/kg (46 ± 12, p < 0.01 and 19 ± 8, p < 0.001 
respectively) was observed compared to the colitic 
group (107 ± 38). In the experimental evaluation 
of the effect of Cd­HexP, a significant reduction was 
observed at doses of 31.25 and 62.5 mg/kg (52 ± 18, 
p < 0.01 and 21 ± 7, p < 0.001 respectively), when 
compared to the colitic animals (101 ± 45) (Table 1).
For the lesion score, Cd­EtOHE at doses of 62.5 
and 125 mg/kg significantly reduced the amounts of 
lesion to 4.0 (1­5) (p < 0.05) and 3.0 (2­5) (p < 0.01) 
respectively, compared to the colitic control of 6 (5­7). 
Cd­HexP 31.25 and 62.5 mg/kg significantly reduced 
lesion to 5.0 (1­6) (p < 0.05) and 5.0 (4­5) (p < 0.01) 
respectively, compared to the colitic group of 7 (5­8) 
(Table 1).
A significant increase in weight/length for the colitic 
group (148 ± 17, p < 0.001, 154 ± 27, p < 0.001) 
was also observed when compared to the non­colitic 
group (110 ± 8, 102 ± 14 respectively). Treatment 
with different doses of Cd­EtOHE (31.25, 62.5, 125 and 
250 mg/kg) did not reduce the weight/length ratio (152 
± 19, 146 ± 19, 134 ± 5 and 152 ± 14 respectively) 
for the parameter compared to the colitic group (148 
± 17). However, treatment with Cd­HexP at a dose of 
62.5 mg/kg significantly reduced the ratio to 129 ± 20 
(p < 0.05), compared to their respective colitic group 
(154 ± 27) (Table 1). 
The administration of TNBS resulted in a diarrhea 
rate of 100% in the colitic animals. Cd­EtOHE at a 
dose of 125 mg/kg significantly reduced the diarrhea 
involvement to 14%. For Cd­HexP, treatment at dose 
of 62.5 mg/kg significantly reduced diarrhea to 29% 
(p < 0.05) when compared to their respective colitic 
control (87%) (Table 1).
Intestines of colitic, non­colitic and treated rats with 
different tested doses of Cd­EtOHE or Cd­HexP in the 
model can be seen in Figures 1 and 2 respectively.
Investigation of Cd-EtOHE and Cd-HexP effects in 
chronic phase intestinal inflammation with induced 
relapse using TNBS in rats 
A significant reduction in macroscopic damage scores 
was observed for both Cd­EtOHE (125 mg/kg) and Cd­
HexP (62.5 mg/kg), to 1.0 (1­4) (p < 0.05) and 1.0 (1­4) 
(p < 0.01) respectively, compared to the colitic control 
4 (3­6). Moreover, the tested plant sample reduced 
the onset of diarrhea by 56% when compared to colitic 
animals (94%) (see Table 2).
The weight/length ratio significantly increased in 
the colitic, Cd­EtOHE and Cd­HexP groups (143 ± 14, 
p < 0.001; 132 ± 11, p < 0.001; 122 ± 12, p < 0.01, 
respectively) compared to the non­colitic group (97 ± 
9). However, Cd­HexP 62.5 mg/kg caused a significant 
reduction (122 ± 12, p < 0.01), compared to the 
colitic group (143 ± 14). These results are shown in 
Table 2, and can be seen best in Figure 3.
A significant decrease in water (28 ± 3, p < 0.01) 
and food (19 ± 2, p < 0.01) intake was observed in 
the colitic group, compared to the non­colitic animals 
(31 ± 4 and 22 ± 2 respectively). Only treatment with 
Cd­HexP increased water (31 ± 2, p < 0.05) and food 
(22 ± 3, p < 0.01) intake, compared to colitic animals 
(28 ± 3, p < 0.01 and 19 ± 2, p < 0.01 respectively) 
(Table 3).
As an additional parameter to the data described 
above, we evaluated the effect of repeated admini­
strations of Cd­EtOHE (125 mg/kg) and Cd­HexP (62.5 
mg/kg) on the body weights of animals affected with 
intestinal inflammation. At the end of the experiment, 
there was a significant reduction in mean body 
weight for the colitic group (215 ± 21, p < 0.001) 
when compared to the non­colitic group (261 ± 35). 
However, when the treatments were performed with 
Cd­HexP (62.5 mg/kg), a significant increase in mean 
body weight (239 ± 17, p < 0 05) was observed 
compared to the colitic animals (215 ± 21) (Table 4).
A significant increase was observed in spleen weight 
Table 1  Effects of oral administration of Cd -EtOHE or Cd -HexP in acute phase of intestinal inflammation in trinitrobenzenesulfonic 
acid-induced ulcerative colitis in rats
Group Dose (mg/kg) ULA (mm2) Inhibition (%) Lesion score Weight/length (mg/cm) Diarrhea (%)
Non-colitics - - 100   110 ± 7.7     0
Colitics - 107 ± 38 - 6.0 (5-7)   148 ± 17f 100
Cd-EtOHE   31.25   79 ± 31   26 5.0 (3-7)   152 ± 19f 100
62.5    46 ± 12b   57  4.0 (1-5)a   146 ± 19f   57
125  19 ± 8c   82  3.0 (2-5)b 134 ± 5d    14b
250   76 ± 23   29 6.0 (4-7)   152 ± 14f   86
Non-colitics - - - -  102 ± 14     0
Colitics - 101 ± 45 - 7.0 (5-8)   154 ± 27f   87
Cd-HexP   31.25    52 ± 18b   49  5.0 (1-6)a   142 ± 20e   87
62.5  21 ± 7c   79  5.0 (4-5)b   129 ± 20a    29a
125   95 ± 33     7 6.0 (5-6)   154 ± 10f   71
250   80 ± 12   22 5.0 (4-7)   155 ± 16f   86
Results expressed as mean ± SD or median (minimum-maximum) of the parameters analyzed (n = 5-8). For the parametric data, mean ± SD was used, with 
ANOVA and a posteriori Dunnett’s test. For the non-parametric data, median (minimum-maximum) was used, with Kruskal-Wallis test and a posteriori 
Dunn. aP < 0.05, bP < 0.01 and cP < 0.001 vs colitic group; dP < 0.05, eP < 0.01 and fP < 0.001 vs non-colitic group. Cd: Combretum duarteanum; EtOHE: Ethanolic 
extract; HexP: Hexane phase.
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in the colitic group (2.8 ± 0.5, p < 0.05) compared 
to the non­colitic group (2.1 ± 0.2). Analyzing the 
organs of animals treated with Cd­EtOHE or Cd­HexP, a 
significant increase in spleen weight for animals treated 
with Cd­EtOHE as compared to the non­colitic group 
was demonstrated (Table 5). In other evaluations (heart, 
liver and kidneys) no significant changes, compared to 
the non­colitic group, were observed.
Histological analysis
Histological examination of the colon of non­colitic 
rats showed normal histological structure, highlighting 
the structure of the mucosal straight intestinal glands 
with large numbers of goblet cells and lamina propria 
classical (or normal). The animals belonging to the 
colitic group had transmural inflammation, necrosis 
of the mucosa with disruption of glands, and loss of 
goblet and epithelial cells. The presence of granulation, 
highlighting neutrophilic and lymphocytic infiltration, 
was also observed.
Treatment with Cd­EtOHE (125 mg/kg) or Cd­HexP 
(62.5 mg/kg) maintained some areas of the mucosal 
structure and epithelium intact, reducing the reducing 
the Inflammatories cells in lamina propria as compared 
to the colitic group, suggesting the re­epithelialization 
of the animals treated with the vegetable samples 
(Figure 4). 
Quantification of MPO activity
According to the results obtained, there was a significant 
increase in MPO to 40.270 ± 3.077 (p < 0.001) in the 
colitic group when compared to non­colitics (10.120 ± 
1.672). When compared to the colitic controls (40.270 
± 3.077), treatments with Cd­EtOHE (15.187 ± 1.158, 
p < 0.001) or Cd­HexP (17.620 ± 2.395, p < 0.001) 
significantly reduced MPO (Figure 5).
A B
C D
E F
Figure 1  Representative macroscopic images of rat colonic mucosa in non-colitics (A), colitics (B), Cd-EtOHE at 31.25 mg/kg (C), Cd-EtOHE at 62.50 mg/kg 
(D), Cd-EtOHE at 125 mg/kg (E), and Cd-EtOHE at 250 mg/kg (F). Cd: Combretum duarteanum; EtOHE: Ethanolic extract.
de Morais Lima GR et  al. Combretum duarteanum
1359 February 28, 2017|Volume 23|Issue 8|WJG|www.wjgnet.com
Assessment of the involvement of pro-inflammatory 
(TNF-α  and IL-1β ) and anti-inflammatory cytokines 
(IL-10)
The results showed a significant increase in TNF­α 
levels in colitic animals (2.0 ± 0.2, p < 0.01) compared 
to non­colitics (1.3 ± 0.1). However, the treatment 
of Cd­EtOHE (125 mg/kg) or Cd­HexP (62.5 mg/kg) 
resulted in TNF­α level reduction (1.2 ± 0.2 and 1.4 
± 0.1, p < 0.01) respectively, compared to the colitic 
group (2.0 ± 0.2) (Figure 5).
IL­1β levels increased in colitic animals (63 ± 6, 
p < 0.001) when compared to the non­colitic group 
(32 ± 4.0). Treatment with Cd­EtOHE significantly 
reduced to 41 ± 5 (p < 0.01) IL­1­β, compared to 
the colitic group (63 ± 6.2). Cd­HexP did not cause 
significant change when compared to the negative 
control (Figure 5).
The results showed significant reduction of IL­10 
in intestinal tissues, comparing the colitic group 3.2 
± 0.3 (p < 0.05) to the non­colitic group (5.1 ± 0.8). 
Treatment with Cd­EtOHE or Cd­HexP caused significant 
increases (5.0 ± 0.4, p < 0.05, 5.8 ± 0.3, p < 0.01, 
respectively) when compared to the colitic group (3 2 ± 
0.3) (Figure 5). 
Immunohistochemical analysis (COX-2, PCNA and SOD 
expression)
In analyzing the results of COX­2 expression shown 
in Table 6 and Figure 6, we observed a significant 
increase in COX­2 expression in the colitic group 
animals to 505 (100­1450) (p < 0.05) when compared 
the non­colitic group of 230 (110­700). However, treat­
ment with Cd­EtOHE (125 mg/kg) or Cd­HexP (62.5 
mg/kg) significantly reduced the expression of COX­2 
to 90 (10­2590) (p < 0.001) and 205 (20­790) (p < 
0.001) respectively, compared to the colitic group of 
505 (100­1450).
A significant increase in PCNA expression was 
observed in the animals of the colitic group of 5380 
(850­15960) (p < 0.001) when compared to the 
non­colitic group of 1425 (60­7890). However, treat­
ment with Cd­EtOHE (125 mg/kg) or Cd­HexP (62.5 
mg/kg) significantly reduced PCNA expression to 1.630 
(90­14790) (p < 0.001) and 1.570 (250­9500) (p < 
A B
C D
E F
Figure 2  Representative macroscopic images of rat colonic mucosa in non-colitics (A), colitics (B), Cd-HexP at 31.25 mg/kg (C), Cd-HexP at 62.50 mg/kg (D), 
Cd-HexP at 125 mg/kg (E), and Cd-HexP at 250 mg/kg (F). Cd: Combretum duarteanum; HexP: Hexane phase.
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0.001) respectively, compared to 5.380 of the colitic 
group (850­15960) (p < 0.001) (Table 6 and Figure 6).
The results of this analysis demonstrated a sig­
nificant decrease in the expression of SOD in colitic 
controls to 165 (10­1000) (p < 0.001) when compared 
to the non­colitic group of 400 (80­1115). The treat­
ment of the animals with Cd­EtOHE (125 mg/kg) or 
Cd­HexP (62.5 mg/kg) increased the expression of 
SOD to 400 (50­1480) (p < 0.05) and 435 (20­1650) (p 
< 0.001) respectively, compared to the colitic control 
(Table 6 and Figure 6).
DISCUSSION
A promising area for research, many plant species and 
their chemical constituents exert therapeutic actions. 
This has led to the development of new, effective and 
safe drugs for the treatment of various pathological 
processes. There is also an interest in targeted therapy 
for diseases derived from oxidative stress, such as 
IBD[11,25].
IBDs are progressive and destructive chronic 
disorders of the GI tract, the most common being 
CD or UC. There is evidence that the pathogenesis of 
IBD is related to a dysfunctional interaction between 
the bacteria of the intestinal microflora and mucosal 
immune system[26,27].
CD and UC are immunologically different diseases. 
CD is characterized by an exaggerated cellular Th1 
response (CD4+) and Th17, characterized by high levels 
of INF­γ/IL­17 and IL­12/IL­23. UC is characterized by 
a heightened Th2 response, and excessive IL­5 and 
IL­13[28­30].
TNBS is a hapten, administered by enema in 
rats in combination with 50% ethanol to break the 
mucus barrier and facilitate penetration of the hapten 
into the intestinal epithelium. TNBS reacts with 
autologous proteins and stimulates the development 
of hypersensitivity, leading to the activation of antigen­
specific T cells. The immune response induced by 
the hapten causes severe ulceration of the mucosal 
and epithelial barrier, characterized by trans­mural 
infiltration of mononuclear cells[20].
Preventive treatment with Cd­EtOHE (62.5 to 
125 mg/kg) or Cd­HexP (31.25 and 62.5 mg/kg) 
caused a significant reduction in the severity and 
extent of injury as reflected in the macroscopic lesion 
score. The macroscopic/microscopic damage scores 
and colon weight/length ratio can be considered as 
sensitive and reliable markers to estimate the severity 
of the disease, and thus the anti­inflammatory effect 
promoted by the test drug[31].
A low incidence of diarrhea in animals treated with 
Cd­EtOHE and Cd­HexP was also observed. Diarrhea 
is a major symptom of disease in both animals and 
humans and indicates loss of the absorptive capacity 
of the colon, which is impaired in intestinal infla­
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Group Dose 
(mg/kg)
Lesion score Weight/length 
(mg/cm)
Diarrhea (%)
Non-colitics - 97 ± 9   0
Colitics - 4.0 (3-6)  143 ± 14f 94
Cd-EtOHE 125  1.0 (1-4)a  132 ± 11f  56a
Cd-HexP      62.5  1.0 (1-4)b    122 ± 12b,e  56a
Results expressed as mean ± SD or median (minimum-maximum) of the 
parameters analyzed (n = 7-9). For the parametric data, mean ± SD was 
used, with ANOVA and a posteriori Dunnett’s test. For non-parametric 
data, median (minimum-maximum) was used, with Kruskal-Wallis test 
and a posteriori Dunn. aP < 0.05, bP < 0.01 vs colitic group; eP < 0.01 and fP 
< 0.001 vs non-colitic group. Cd: Combretum duarteanum; EtOHE: Ethanolic 
extract; HexP: Hexane phase.
Table 2  Effects of oral administration of Cd -EtOHE or Cd -
HexP in chronic phase with relapse of intestinal inflammation 
in trinitrobenzenesulfonic acid-induced ulcerative colitis in 
rats
Group Dose (mg/kg) Water intake (mL) Food intake (g)
Non-colitics - 31 ± 4 22 ± 2
Colitics -   28 ± 3e  19 ± 2e
Cd-EtOHE 125 30 ± 4  20 ± 3d
Cd-HexP      62.5   31 ± 2a  22 ± 3b
Values are expressed as mean ± SD (n = 7-9). One-way ANOVA, followed 
by Dunnett's test, aP < 0.05 and bP < 0.01 vs colitic group; dP < 0.05 and eP 
< 0.01 vs non-colitic group. Cd: Combretum duarteanum; EtOHE: Ethanolic 
extract; HexP: Hexane phase.
Table 3  Effect of oral administration of Cd -EtOHE or 
Cd -HexP for 21 d on water and food consumption in 
trinitrobenzenesulfonic acid-induced ulcerative colitis in rats
Group Initial weight (g) Final weight (g) Average increase (g)
Non-colitics 202 ± 32   261 ± 35   51 ± 10
Colitics 189 ± 19    215 ± 21f    35 ± 12d
Cd-EtOHE 178 ± 13 230 ± 7 43 ± 6
Cd-HexP 184 ± 14    239 ± 17a    48 ± 10a
Values are expressed as mean ± SD (n = 7-9). One-way ANOVA, followed 
by Dunnett's test, aP < 0.05 vs colitic group; dP < 0.05, fP < 0.001, vs non-
colitic group. Cd: Combretum duarteanum; EtOHE: Ethanolic extract; HexP: 
Hexane phase.
Table 4  Effect of oral administration of Cd -EtOHE or Cd -
HexP for 21 d on body weight on trinitrobenzenesulfonic 
acid-induced ulcerative colitis in rats
Group Heart Liver Kidneys Spleen
Non-colitics 4.0 ± 0.2 41 ± 1.5 8.6 ± 0.6 2.1 ± 0.2
Colitics 4.0 ± 0.5 43 ± 5.3 8.6 ± 1.0  2.8 ± 0.5d
Cd-EtOHE 4.0 ± 0.3 43 ± 3.1 8.6 ± 0.2  2.8 ± 0.4e
Cd-HexP 4.0 ± 0.3 44 ± 1.2 8.4 ± 0.5 2.4 ± 0.2
Values are expressed as mean ± SD (n = 7-9). One-way ANOVA, followed 
by Dunnett's test, dP < 0.05 and eP < 0.01 vs non-colitic group. Cd: Combretum 
duarteanum; EtOHE: Ethanolic extract; HexP: Hexane phase.
Table 5  Effect of oral administration of Cd -EtOHE or Cd -
HexP for 21 d on weight organs in trinitrobenzenesulfonic 
acid-induced ulcerative colitis in rats
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mmation[32]. The results suggest that treatment with 
the plant samples restored the intestinal absorptive 
capacity.
Cd­HexP at 62.5 mg/kg significantly reduced the 
weight/length ratio. This effect is possibly related to 
the scavenging capacity of free radicals caused by 
treatment at this dose[33]. These results demonstrate, 
for the first time, anti­inflammatory intestinal activity 
for a species belonging to the genus Combretum.
The more effective doses of Cd­EtOHE (125 mg/kg) 
or Cd­HexP (62.5 mg/kg) were selected to investigate 
their effects in the chronic phase with relapse in TNBS­
induced UC in rats. This model mimics the disease in 
humans and can be used to evaluate new treatments 
potentially applicable in IBD[31]. 
Cd­EtOHE at 125 mg/kg or Cd­HexP at 62.5 mg/kg 
A B
C D
Figure 3  Representative macroscopic images of rat colonic mucosa in non-colitics (A), colitics (B), Cd-EtOHE at 125 mg/kg (C), and Cd-HexP at 62.5 mg/kg (D). 
Cd: Combretum duarteanum; HexP: Hexane phase; EtOHE: Ethanolic extract.
Figure 4  Representative histological appearance of rat colonic mucosa in the non-colitic group (A), colitic group (B), Cd-EtOHE (C), and Cd-HexP (D). 
Aumento magnification × 40 (*goblet cells; → ulceration region; 50 μm). Colonic tissue sections were stained with hematoxylin and eosin, and observed under light 
microscope (magnification × 40). Cd: Combretum duarteanum; HexP: Hexane phase; EtOHE: Ethanolic extract.
*
*
A B
C D
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significantly decreased signs of disease, such as macro­
scopic lesion (lesion area and score), weight/length 
ratio and diarrhea, showing the anti­inflammatory 
effect at 21 d of treatment.
Intestinal inflammation in the TNBS­induced model 
promoted the loss of 8% to 10% of body weight 
notably at 1 wk after induction, this is related to 
reduction in food intake due to abdominal pain and 
diarrhea during the active phase of the disease[34]. 
Treatment with Cd­HexP at 62.5 mg/kg reversed low 
water and food intake (and body weight loss) caused 
by disease. 
The spleen recycles and acts as a reserve of 
red blood cells. The organ is the center of reticulo­
endothelial system activity, and is an essential part of 
the immune system[35]. A significant increase in spleen 
weight of colitic animals when compared to non­colitic 
animals was demonstrated. UC and CD are mentioned 
in lists of factors that can cause increased spleen size, 
which can occur through lymphoid cell accumulation in 
immune functions[35,36].
MPO is an enzyme found in neutrophils and has 
been used as a quantitative index of neutrophil influx 
into inflamed intestines. The recruitment and activation 
of neutrophils results in a significant increase in free 
radical production, capable of overcoming antioxidant 
protections, and resulting in oxidative stress and 
inflammation[37,38]. Cd­EtOHE at 125 mg/kg and Cd­
HexP at 62.5 mg/kg significantly decreased MPO 
activity when compared to colitic animals. This may 
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Figure 5  Effect of acute administration of Cd-EtOHE at 125 mg/kg and Cd-HexP at 62.5 mg/kg on myeloperoxidase activity (MPO, U/mg protein) (A), tumor 
necrosis factor-alpha (TNF-α, pg/mg protein) (B), interleukin-1β (IL-1β, pg/mg protein) (C), interleukin-10 (IL-10, pg/mg protein) (D) in trinitrobenzene 
sulfonic acid-induced colitis model with relapse in rats (TNBS, 10 mg/animal). Data are expressed as the mean ± SEM. aP < 0.05, bP < 0.01 and cP < 0.001 vs 
colitic group. dP < 0.05, eP < 0.01 and fP < 0.001 vs non-colitic group. Cd: Combretum duarteanum; HexP: Hexane phase; EtOHE: Ethanolic extract.
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Group Dose (mg/kg) COX-2 (μm2) PCNA (μm2) SOD (μm2)
Non-colitics -  230 (110-700) 1425 (60-7890) 400 (80-1.115)
Colitics -      505 (100-1.450)d       5380 (850-15.960)f  165 (10-1.000)f
Cd-EtOHE 125      90 (10-2.590)c     1630 (90-14.790)c  400 (50-1.480)c
Cd-HexP      62.5 205 (20-790)c     1570 (250-9.500)c  435 (20-1.650)c
Results are expressed as median (minimum-maximum) of the analyzed parameters (n = 7-9). For nonparametric data, median (minimum-maximum) was 
used, with Kruskal-Wallis and Dunn’s test a posteriori. cP < 0.001 vs colitic group; dP < 0.05 and fP < 0.001 vs non-colitic group. COX-2: Cyclooxygenase-2; 
PCNA: Proliferating cell nuclear antigen; SOD: Superoxide dismutase; Cd: Combretum duarteanum; EtOHE: Ethanolic extract; HexP: Hexane phase.
Table 6  Effect of oral administration of Cd -EtOHE or Cd -HexP for 21 d on the expression of cyclooxygenase-2, proliferating cell 
nuclear antigen and superoxide dismutase in trinitrobenzenesulfonic acid-induced ulcerative colitis in rats
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be interpreted as a manifestation of anti­inflammatory 
effect for C. duarteanum species.
The inflammation in the TNBS­induced colitis model 
is characterized by a Th1 pathway immune response, 
in which there is an increase in TNF­α, IL­1β, IL­12, 
IL­17, IL­18 and IL­6[39­41]. 
Up­regulation of the inflammatory state with 
increased TNF­α and IL­1β levels in colitic rats was 
observed, which corroborates the literature findings[42]. 
The treatment with Cd­EtOHE at 125 mg/kg or 
Cd­HexP at 62.5 mg/kg was able to significantly 
reduce TNF­α levels when compared to the colitic 
controls, suggesting that TNF­α suppression is related 
to the anti­inflammatory effect promoted by the 
vegetable samples studied. Cd­EtOHE at 125 mg/kg 
was able to decrease IL­1β levels, suggesting that 
compounds of this plant sample may interfere with the 
synthesis machinery of IL­1β activation by inhibiting 
production[10,43,44].
IL­10 suppresses production of pro­inflammatory 
cytokines, such as IL­12, IL­6, IL­1 and TNF­α, in 
activated macrophages in vitro, and blocks the 
ability of macrophages stimulating the production 
of interferon by Th1 cells. IL­10 is produced in 
large amounts by TCD4+ regulatory cells subtype 
(Tregs). Tregs maintain homeostasis by suppressing 
the adaptive response of T cells and preventing 
autoimmunity[45].
A significant elevation in IL­10 levels in animals 
treated with Cd­EtOHE at 125 mg/kg or Cd­HexP 
at 62.5 mg/kg, compared to the colitic group, 
was demonstrated. This increase is attributable to 
compensatory mechanisms against colonic injury, 
possibly playing a role in reducing mucosal inflammation 
and preventing it from becoming uncontrolled. IL­10 
down­regulates antigen presentation, and thereafter the 
release of pro­inflammatory cytokines such as TNF­α, 
IL­1β and IL­6[46,47].
Studies have shown that COX­2 is expressed 
predominantly in experimental colitis. Colotic humans 
and animals show considerable improvement in the 
inflammatory process when COX­2 inhibitors are 
used[48]. The vegetable samples tested prevented the 
increase in expression of this enzyme, and suggest 
that the intestinal anti­inflammatory effect promoted 
by Cd­EtOHE at 125 mg/kg or Cd­HexP at 62.5 mg/kg 
is mediated by a reduction in COX­2 expression.
PCNA is an intra­nuclear protein, whose expression 
is related to cell proliferation and DNA repair. It 
is highly expressed during the S phase of the cell 
cycle[49]. Studies show that PCNA expression is up­
regulated during chronic inflammation, inducing the 
proliferation of epithelial cells to repair the mucous 
tissue[50,51].
The positive expression of PCNA was increased 
in colitic animals in this study, while Cd­EtOHE at 
125 mg/kg or Cd­HexP at 62.5 mg/kg treatment 
significantly decreased expression of this protein. 
Treatment with the plant samples studied protected 
against intestinal epithelial cell damage induced by 
TNBS and the effect was mediated via regulation of 
PCNA.
AⅠ BⅠ CⅠ DⅠ
AⅡ BⅡ CⅡ DⅡ
AⅢ BⅢ CⅢ DⅢ
Figure 6  Photomicrograph of colonic samples from rats submitted to trinitrobenzene sulfonic acid-induced colitis model with relapse in rats after 21 d of 
treatment. A: Non-colitic group; B: Colitic group; C: Cd-EtOHE at 125 mg/kg; D: Cd-HexP at 62.5 mg/kg. Immunohistochemical localization of Line Ⅰ: COX-2; Line Ⅱ: 
PCNA; Line Ⅲ: SOD (→ COX-2, PCNA and SOD respectively). COX-2: Cyclooxygenase-2; PCNA: Proliferating cell nuclear antigen; SOD: Superoxide dismutase; 
Cd: Combretum duarteanum; HexP: Hexane phase; EtOHE: Ethanolic extract.
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SOD is a key enzyme that converts superoxide 
to H2O2, a more stable metabolite. During oxidative 
stress and inflammation, SOD activity is decreased 
in inflamed tissues as compared to non­inflamed 
tissues. The decreased SOD activity allows superoxide 
accumulation and subsequent oxidative effects in the 
intestinal tissue, as well as increased expression of 
adhesion molecules[52]. 
Treatment with Cd­EtOHE at 125 mg/kg or Cd­HexP 
at 62.5 mg/kg significantly increased the expression 
of this enzyme when compared to colitic animals, 
suggesting involvement of an antioxidant effect in the 
intestinal anti­inflammatory activity promoted by the 
vegetable samples.
In conclusion, C. duarteanum presents promising 
anti­inflammatory intestinal effects that are related 
to reduced levels of the pro­inflammatory cytokines 
(TNF­α and IL­1β) and increased anti­inflammatory 
cytokine (IL­10), which feature regulatory effects on 
the immune response, with reduction in the expression 
of COX­2, PCNA, and an increase in the antioxidant 
enzyme SOD. 
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Background
A variety of herbal medicines have been shown to produce promising results 
in the treatment of peptic ulcer and inflammatory bowel disease. Combretum 
duarteanum (C. duarteanum, Cd), the species selected for this study, is 
popularly known as “mufumbo, cipiúba, cipaúba”. In folk medicine, it is used to 
treat pain, inflammation and gastrointestinal (GI) tract disorders. Given the need 
for new inflammatory bowel disease therapies, this study aimed to evaluate, for 
the first time, the intestinal anti-inflammatory activity promoted by the species 
C. duarteanum, validating its popular use and contributing to the search for new 
therapies for diseases that affect the GI tract.
Research frontiers
C. duarteanum has presented in vitro and in vivo anti-inflammatory, 
antinociceptive and antioxidant capacities. Furthermore, it has demonstrated 
low toxicity, gastroprotective and antiulcer activity in different models of acute 
ulcer induction (acidified ethanol, ethanol, nonsteroidal anti-inflammatory drugs, 
stress, pylorus ligature and acetic acid) in animals. 
Innovations and breakthroughs
This study evaluated, for the first time, the intestinal anti-inflammatory activity 
promoted by the species C. duarteanum Cambess.
Applications
This study validated the popular use of C. duarteanum and contributes to the 
search for new therapies for diseases that affect the GI tract.
Peer-review
The authors demonstrated that Cd-EtOHE and Cd-HexP obtained from leaves 
of C. duarteanum displays anti-inflammatory effect in trinitrobenzenesulfonic 
acid colitis model in rats. These results are promising. The vegetal samples 
may have a role in antioxidant activity and mucosal healing in ulcerative colitis.
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